DBV Technologies Announces Results of its 2021 Ordinary and
Extraordinary General Meeting and the Appointment of Dr. Adora Ndu,
Pharm.D., J.D., and Dr. Ravi Madduri Rao, M.D., Ph.D., as Members
of its Board of Directors
Montrouge, France, May 19, 2021
DBV Technologies Announces Results of
its 2021 Ordinary and Extraordinary General Meeting
and the
Appointment of Dr. Adora
Ndu, Pharm.D., J.D., and Dr. Ravi
Madduri Rao, M.D., Ph.D., as
Members of its Board of
Directors
DBV Technologies (Euronext: DBV – ISIN:
FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage
biopharmaceutical company, today held its Ordinary and
Extraordinary General Meeting. DBV Technologies’ General Meeting
was chaired by Michel de Rosen, Chairman of DBV Technologies’ Board
of Directors, in a closed virtual session without the physical
presence of shareholders or any other person authorized to attend,
at DBV Technologies’ registered office.
The Company’s shareholders approved all
resolutions for which DBV Technologies’ Board of Directors
recommended a vote in favor. These resolutions and their results
are posted on the Investors & Media section of the Company’s
website: https://www.dbv-technologies.com/investor-relations/financial-information/annual-reports/.
The Company’s shareholders have elected Dr.
Adora Ndu, Pharm.D., J.D., and Dr. Ravi Madduri Rao, M.D., Ph.D.,
as independent directors, effective immediately. Dr. Torbjorn
Bjerke, MD, a long-time member of the Board of Directors of DBV
Technologies, has decided to retire and is leaving the Board
effective today. The Board of DBV Technologies now comprises 10
directors.
“We are pleased with the outcome of DBV
Technologies’ Ordinary and Extraordinary General Meeting. We are
proud to welcome Adora and Ravi as new independent directors, and
we are delighted to have added such accomplished professionals to
DBV Technologies’ Board. On behalf of the whole Board of Directors,
I would also like to thank Torbjorn for his many years of sound
advice and expertise.” said Michel de Rosen. “Today’s appointments
reflect a continued commitment to the development of Viaskin Peanut
and DBV Technologies’ pipeline by adding the expertise that both
Adora and Ravi have demonstrated throughout their careers. We are
confident that they will complement our team and help us pursue our
strategic objectives.”
Dr. Ndu is currently the Group Vice President,
Head of Worldwide Research and Development Strategy, Scientific
Collaborations and Policy at BioMarin Pharmaceutical. She brings
over 15 years of complementary experience in drug development and
regulatory affairs. Dr. Ndu has spent seven years in various
leadership roles in the biopharmaceutical sector. Her expertise
incorporates regulatory strategy, patient engagement, prescription
drug promotion, and policy for U.S. and international markets.
Additionally, Dr. Ndu spent eight years at the U.S. Food and Drug
Administration, Center for Drug Evaluation and Research, where she
progressed in leadership serving most recently as Director for the
Division of Medical Policy Development and Commander in the U.S.
Public Health Service. She has been involved in the registrations
of multiple products globally and is a respected thought leader in
regulatory science, having played a significant role in developing
and evaluating guidance, as well as shaping regulatory
policy. Dr. Ndu received her doctorate in pharmacy from
Howard University’s College of Pharmacy and a law degree from the
University of Maryland.
“I am thrilled to join DBV Technologies’ Board
of Directors and to support DBV’s efforts to advance breakthrough
food allergy treatments for patients,” Dr. Ndu said. “Viaskin and
Epicutaneous Immunotherapy represent an innovative and promising
drug development platform. I look forward to collaborating
alongside knowledgeable and committed Board of Directors team at
this pivotal point in Viaskin development.”
Dr. Rao is currently the Global Head of Research
and Development and Chief Medical Officer at Swedish Orphan
Biovitrum (Sobi), where he leads Sobi’s efforts to advance
therapeutic treatments for rare diseases in hematology and
immunology. Dr. Rao is a well-known research and development
professional and clinician with nearly fifteen years of experience
in the biopharmaceutical sector, including experience in early and
late-stage development, approval and launches of new drugs across
multiple therapeutic areas. Previously, he was an academic
rheumatologist at Imperial College and a post-doctoral fellow at
Harvard University. Dr. Rao is a Member of the Royal College of
Physicians, London, and an Honorary Member of the Faculty of
Pharmaceutical Medicine.
“Joining DBV Technologies’ Board of Directors
presents an exciting opportunity for me to help guide DBV
Technologies as the company continues to pursue potential
regulatory approval of Viaskin Peanut,” said Dr. Rao. “I really
believe in the Viaskin technology. It is compelling and has the
potential to lead to the development of transformational medicines
for many. I am eager to leverage my medical and drug development
experience to support the Board and the management team in planning
and implementing DBV Technologies’ strategic mission.”
DBV Technologies’ shareholders have also
ratified the appointment of Mr. Timothy E. Morris as an independent
member of DBV Technologies’ Board of Directors. Mr. Morris’
cooption, effective March 30, 2021, was subject to the shareholders
vote at the General Meeting.
About DBV Technologies DBV
Technologies is developing Viaskin™, an investigational proprietary
technology platform with broad potential applications in
immunotherapy. Viaskin is based on epicutaneous immunotherapy, or
EPIT™, DBV Technologies’ method of delivering biologically active
compounds to the immune system through intact skin. With this new
class of non-invasive product candidates, the Company is dedicated
to safely transforming the care of food allergic patients. DBV
Technologies’ food allergies programs include ongoing clinical
trials of Viaskin Peanut. DBV Technologies has global headquarters
in Montrouge, France and North American operations in Summit, NJ
The Company’s ordinary shares are traded on segment B of Euronext
Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120
index, and the Company’s ADSs (each representing one-half of one
ordinary share) are traded on the Nasdaq Global Select Market
(Ticker: DBVT).
Forward Looking StatementsThis
press release may contain forward-looking statements and estimates,
including statements regarding DBV Technologies’ strategic
objectives, DBV Technologies’ pursuit of regulatory approval of
Viaskin Peanut, and the ability of any of DBV Technologies’ product
candidates, if approved, to improve the lives of patients with food
allergies. These forward-looking statements and
estimates are not promises or guarantees and involve substantial
risks and uncertainties. At this stage, DBV Technologies’ product
candidates have not been authorized for sale in any country. Among
the factors that could cause actual results to differ materially
from those described or projected herein include uncertainties
associated generally with research and development, clinical trials
and related regulatory reviews and approvals, including the impact
of the COVID-19 pandemic. A further list and description of risks
and uncertainties that could cause actual results to differ
materially from those set forth in the forward-looking statements
in this press release can be found in DBV Technologies’ regulatory
filings with the French Autorité des Marchés Financiers (“AMF”),
DBV Technologies’ filings and reports with the U.S. Securities and
Exchange Commission (“SEC”), including in DBV Technologies’ Annual
Report on Form 10-K for the year ended December 31, 2020, filed
with the SEC on March 17, 2021, and future filings and reports made
with the AMF and SEC by DBV Technologies. Existing and prospective
investors are cautioned not to place undue reliance on these
forward-looking statements and estimates, which speak only as of
the date hereof. Other than as required by applicable law, DBV
Technologies undertakes no obligation to update or revise the
information contained in this Press Release.
DBV Investor Relations Contact
Anne Pollak+ 1 (857) 529-2363anne.pollak@dbv-technologies.com
DBV Media Contact Angela
Marcucci+1 (646) 842-2393angela.marcucci@dbv-technologies.com
DBV Technologies (EU:DBV)
Historical Stock Chart
From Feb 2024 to Mar 2024
DBV Technologies (EU:DBV)
Historical Stock Chart
From Mar 2023 to Mar 2024